Postibrutinib outcomes in patients with mantle cell lymphoma

Author:

Martin Peter1,Maddocks Kami2,Leonard John P.1,Ruan Jia1,Goy Andre3,Wagner-Johnston Nina4,Rule Simon5,Advani Ranjana6,Iberri David6,Phillips Tycel7,Spurgeon Stephen8,Kozin Eliana8,Noto Katherine1,Chen Zhengming9,Jurczak Wojciech10,Auer Rebecca11,Chmielowska Ewa12,Stilgenbauer Stephan13,Bloehdorn Johannes13,Portell Craig14,Williams Michael E.14,Dreyling Martin15,Barr Paul M.16,Chen-Kiang Selina17,DiLiberto Maurizio17,Furman Richard R.1,Blum Kristie A.2

Affiliation:

1. Department of Medicine, Weill Cornell Medical College, New York, NY;

2. Ohio State University Comprehensive Cancer Center, Columbus, OH;

3. Hackensack University Medical Center, Hackensack, NJ;

4. Division of Oncology, Washington University School of Medicine, St. Louis, MO;

5. Department of Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry and Derriford Hospital, Plymouth, United Kingdom;

6. Stanford Cancer Institute, Stanford, CA;

7. Department of Internal Medicine, University of Michigan, Ann Arbor, MI;

8. Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR;

9. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY;

10. Department of Hematology, Jagiellonian University, Krakow, Poland;

11. St. Bartholomew's Hospital, London, United Kingdom;

12. Oddzial Kliniczny Onkologii, Bydgoszcz, Poland;

13. Universitätsklinikum Ulm, Ulm, Germany;

14. University of Virginia Cancer Center, Charlottesville, VA;

15. Klinikum der Universität München, Munich, Germany;

16. Department of Medicine, University of Rochester Medical Center, Rochester, NY; and

17. Department of Pathology, Weill Cornell Medical College, New York, NY

Abstract

Key Points Patients with mantle cell lymphoma who progressed during treatment with ibrutinib have a poor outcome. There are no therapies that appear to be uniquely successful in the postibrutinib setting. The postibrutinib setting is an unmet need.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3